Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3045% below fair value
$0.51−0.03 (-4.67%)
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Invivyd operating margin
Operating margin is operating income as a percentage of revenue.
Invivyd's operating margin for the twelve months ending Jun 30, 2026 was -192.8%. For fiscal 2025 it was -104.0%, against -696.8% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -104.0% | +592.8 |
| FY2024 | Dec 31, 2024 | -696.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -320.8% | −193.0 |
| Q1 FY2026 | Mar 31, 2026 | -313.9% | −164.2 |
| Q4 FY2025 | Dec 31, 2025 | -73.0% | +66.2 |
| Q3 FY2025 | Sep 30, 2025 | -84.0% | +586.1 |
| Q2 FY2025 | Jun 30, 2025 | -127.8% | +2047.4 |
| Q1 FY2025 | Mar 31, 2025 | -149.7% | – |
| Q4 FY2024 | Dec 31, 2024 | -139.1% | – |
| Q3 FY2024 | Sep 30, 2024 | -670.0% | – |
| Q2 FY2024 | Jun 30, 2024 | -2175.2% | – |
See a number that looks wrong?